Fundraising FoxOncoXome
North Hollywood, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into OncoXome
Sign up to see every warm intro you have to OncoXome
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OncoXome team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oncoxome develops an oral delivery platform for cancer therapies that targets tumor cells directly with minimal off-target toxicity. The platform enables delivery of various therapeutic modalities including CRISPR, siRNA, mRNA, and proteins to cancer patients.
Founders & leadership
AG
Auriane GamelinNamed on SEC filing
LG
Laurence GamelinNamed on SEC filing
EG
Erick GamelinNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$170.5K disclosed across 1 round · 2022
▶$170.5KraisedFeb 2023 · 2 investors · BiotechnologyRule 506(b)
▶$170.5KraisedFeb 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Auriane GamelinExecutive Officer, Director
- Laurence GamelinExecutive Officer, Director
- Erick GamelinExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $170.5K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
OncosenxOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
Oncotelic TherapeuticsOncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
Companies working in the same space as OncoXome.
Frequently asked questions
- What does OncoXome do?
- Oncoxome develops an oral delivery platform for cancer therapies that targets tumor cells directly with minimal off-target toxicity. The platform enables delivery of various therapeutic modalities including CRISPR, siRNA, mRNA, and proteins to cancer patients.
- Who are OncoXome's investors?
- OncoXome's investors include The Innovation Space.
- How much funding has OncoXome raised?
- OncoXome has disclosed $170.5K raised across 1 round.
- Where is OncoXome headquartered?
- OncoXome is headquartered in North Hollywood, US.